Psychedelics may be one of the top investment stories of the New Year. The US FDA is supportive of the research, calling psilocybin a breakthrough therapy. Dozens of studies show such treatments are beneficial, including those conducted by Johns Hopkins Medicine and New York University.
For example, psilocybin has been found to help treat mental health issues, such as depression, anxiety, obsessive-compulsive disorder, PTSD, and possibly even eating disorders. It can reportedly activate serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."
LSD may be able to help patients with anxiety disorders and other medical issues.
MDMA-assisted therapy could help treat eating disorders, including anorexia and binge eating.
Even more exciting, a new ETF, the Horizons Psychedelic Stock Index, is expected to start trading Jan. 27, 2021 under ticker PSYK on the NEO Exchange. Psyched Wellness Ltd. (CSE:PSYC)(OTC:PSYCF) will be one of the top listings on the ETF.
"We are pleased to be included in the first psychedelics ETF and to be recognized as one of the leading company in the field of psychedelic health and wellness and pharmaceuticals," said Jeff Stevens, chief executive officer of Psyched. "We are the only publicly traded company working with a legal psychoactive mushroom and we are advancing novel muscimol-based therapeutics using our proprietary extract, AME-1."
This New Psychedelic ETF Could Give the Industry a Boost
“The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to ‘invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances,’” as noted in a recent press release from Mind Cure Health.
Other top psychedelic stocks that will be a part of the ETF include:
COMPASS Pathways (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial resultsfor the third quarter of 2020 and gave an update on recent progress across its business. George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, “This has been a significant quarter, with an IPO that gives us the funds needed to advance our mission and transform mental health care. Recent hires for the company build further important expertise within our strong leadership team, including in data science and digital health, which will be core to the future of mental health care. We remain fully focused on execution of our phase IIb trial investigating our COMP360 psilocybin therapy for treatment-resistant depression and, with scientific partners in our recently established Drug Discovery Center, are also evaluating the potential of early stage compounds to address mental health challenges.”
Havn Life Sciences (CSE:HAVN)(OTC:HAVLF), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it has entered into a definitive agreement to acquire, on the terms and conditions set forth in the Definitive Agreement, all of the outstanding share capital of GCO Packaging and Manufacturing Ltd., which operates a large scale manufacturing, packaging and distribution facility in British Columbia – in exchange for 6,000,000 common shares of Havn Life. Havn Life intends to utilize the Facility to support formulation and manufacturing processes in-house to ensure the highest standards of quality and efficacy. The Acquisition is expected to enable Havn Life to accelerate and scale production of new formulations and products at a single location.
Red Light Holland Corp. (CSE:TRIP)(OTC:TRUFF), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as sole bookrunner and underwriter, 19,610,000 units of the Company, on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $0.255 for gross proceeds of $5,000,550. The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $750,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $5,750,000.
Johnson & Johnson (NYSE:JNJ) announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-based healthcare company, enabled us to lead in the fight against COVID-19. We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come.”
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Psyched Wellness Ltd. by a third party. We own ZERO shares of Psyched Wellness Ltd. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
